相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Visualizing and interpreting cancer genomics data via the Xena platform
Mary J. Goldman et al.
NATURE BIOTECHNOLOGY (2020)
The tumour microenvironment in pancreatic cancer - clinical challenges and opportunities
Won Jin Ho et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
Targeting the HGF/MET Axis in Cancer Therapy: Challenges in Resistance and Opportunities for Improvement
Xing Huang et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2020)
Regulation and modulation of antitumor immunity in pancreatic cancer
Joshua Leinwand et al.
NATURE IMMUNOLOGY (2020)
The AKT-independent MET-V-ATPase-MTOR axis suppresses liver cancer vaccination
Xing Huang et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2020)
Calreticulin couples with immune checkpoints in pancreatic cancer
Xing Huang et al.
CLINICAL AND TRANSLATIONAL MEDICINE (2020)
The HGF-MET axis coordinates liver cancer metabolism and autophagy for chemotherapeutic resistance
Xing Huang et al.
AUTOPHAGY (2019)
Met inhibition revokes IFNγ-induction of PD-1 ligands in MET-amplified tumours
Valentina Martin et al.
BRITISH JOURNAL OF CANCER (2019)
Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation
Sabrina Baltschukat et al.
CLINICAL CANCER RESEARCH (2019)
MET Inhibitors Promote Liver Tumor Evasion of the Immune Response by Stabilizing PDL1
Hui Li et al.
GASTROENTEROLOGY (2019)
Molecular subtypes of pancreatic cancer
Eric A. Collisson et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2019)
Synergistic inhibition of pancreatic cancer with anti-PD-L1 and c-Myc inhibitor JQ1
Yu Pan et al.
ONCOIMMUNOLOGY (2019)
Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment
Ming Yi et al.
MOLECULAR CANCER (2019)
GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis
Zefang Tang et al.
NUCLEIC ACIDS RESEARCH (2019)
Capmatinib for the treatment of non-small cell lung cancer
Johan Filip Vansteenkiste et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2019)
Tumour cell-derived debris and IgG synergistically promote metastasis of pancreatic cancer by inducing inflammation via tumour-associated macrophages
Qi Chen et al.
BRITISH JOURNAL OF CANCER (2019)
The RTK Interactome: Overview and Perspective on RTK Heterointeractions
Michael D. Paul et al.
CHEMICAL REVIEWS (2019)
A Third Shot at EGFR: New Opportunities in Cancer Therapy
Salvador Guardiola et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2019)
A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma
Shukui Qin et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2019)
IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer
Thomas A. Mace et al.
GUT (2018)
Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1
Chia-Wei Li et al.
CANCER CELL (2018)
Mechanisms of receptor tyrosine kinase activation in cancer
Zhenfang Du et al.
MOLECULAR CANCER (2018)
Advances in studies of tyrosine kinase inhibitors and their acquired resistance
Qinlian Jiao et al.
MOLECULAR CANCER (2018)
Therapeutic developments in pancreatic cancer: current and future perspectives
John P. Neoptolemos et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2018)
c-Met affects gemcitabine resistance during carcinogenesis in a mouse model of pancreatic cancer
Kozo Noguchi et al.
ONCOLOGY LETTERS (2018)
Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets
Adam Nagy et al.
SCIENTIFIC REPORTS (2018)
MET/HGF Co-Targeting in Pancreatic Cancer: A Tool to Provide Insight into the Tumor/Stroma Crosstalk
Chiara Modica et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Dual Inhibition of Hedgehog and c-Met Pathways for Pancreatic Cancer Treatment
Agnieszka A. Rucki et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Identification of CMTM6 and CMTM4 as PD-L1 protein regulators
Riccardo Mezzadra et al.
NATURE (2017)
CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity
Marian L. Burr et al.
NATURE (2017)
Tumor Mutational Burden and Response Rate to PD-1 Inhibition
Mark Yarchoan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses
Zefang Tang et al.
NUCLEIC ACIDS RESEARCH (2017)
Correlation of c-MET Expression with PD-L1 Expression in Metastatic Clear Cell Renal Cell Carcinoma Treated by Sunitinib First-Line Therapy
Solene-Florence Kammerer-Jacquet et al.
TARGETED ONCOLOGY (2017)
Immunotherapy in pancreatic ductal adenocarcinoma: an emerging entity?
I. H. Sahin et al.
ANNALS OF ONCOLOGY (2017)
MicroRNA-181b-5p, ETS1, and the c-Met pathway exacerbate the prognosis of pancreatic ductal adenocarcinoma after radiation therapy
Hideo Tomihara et al.
CANCER SCIENCE (2017)
Spatial and Temporal Regulation of Receptor Tyrosine Kinase Activation and Intracellular Signal Transduction
John J. M. Bergeron et al.
ANNUAL REVIEW OF BIOCHEMISTRY, VOL 85 (2016)
Coinhibitory Pathways in Immunotherapy for Cancer
Susanne H. Baumeister et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 34 (2016)
Cancer treatment and survivorship statistics, 2016
Kimberly D. Miller et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2016)
Current progress in immunotherapy for pancreatic cancer
Kelly Foley et al.
CANCER LETTERS (2016)
Dual Faces of IFNγ in Cancer Progression: A Role of PD-L1 Induction in the Determination of Pro- and Antitumor Immunity
Masaki Mandai et al.
CLINICAL CANCER RESEARCH (2016)
Genomic analyses identify molecular subtypes of pancreatic cancer
Peter Bailey et al.
NATURE (2016)
Cdk5 disruption attenuates tumor PD-L1 expression and promotes antitumor immunity
R. Dixon Dorand et al.
SCIENCE (2016)
Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity
Chia-Wei Li et al.
NATURE COMMUNICATIONS (2016)
IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer
K. Abiko et al.
BRITISH JOURNAL OF CANCER (2015)
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
Sandip Pravin Patel et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma
Rafael Winograd et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Jacques Ferlay et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Microenvironment-Derived HGF Overcomes Genetically Determined Sensitivity to Anti-MET Drugs
Selma Pennacchietti et al.
CANCER RESEARCH (2014)
Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States
Lola Rahib et al.
CANCER RESEARCH (2014)
Receptor Tyrosine Kinases: Legacy of the First Two Decades
Joseph Schlessinger
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2014)
Nivolumab plus Ipilimumab in Advanced Melanoma
Jedd D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
A Novel Kinase Inhibitor, INCB28060, Blocks c-MET-Dependent Signaling, Neoplastic Activities, and Cross-Talk with EGFR and HER-3
Xiangdong Liu et al.
CLINICAL CANCER RESEARCH (2011)
Cell Signaling by Receptor Tyrosine Kinases
Mark A. Lemmon et al.
CELL (2010)
Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses
Manish J. Butte et al.
IMMUNITY (2007)
Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-γ-induced upregulation of B7-H1 (CD274)
SJ Lee et al.
FEBS LETTERS (2006)
分享论文
